Praziquantel is filed as Anthelmintic. The sections below restate public label fields stored for this profile.
Diagnostic Chart Gill and Skin Flukes: Very common fish parasites. Can be found on the gills, scales or skin. Not visible without the aid of magnification. Symptoms may include: darkening of skin, clamped fins, excess mucous. Fish may also swim erratically or become emaciated. Hole-in-the-Head Disease: Symptoms include pitting and erosion of skin and muscle tissue around the face and side of body. Many infected fish exhibit poor appetite, weight loss and nervousness. Wasting Disease: Fish parasites transmitted fromn fish to fish cause emaciation, anemia and lethargy.Tissue damage leading to subsequent ulceration of the gastrointestinal tract. Excess mucus and white stringy feces are often produced as a result of parasitic invasion. Swollen Abdomen: Fish infected with tapeworms (cestodes), often have an extended or swollen abdomen. Internal area of attachment results in damaged tissue. Fish normally show signs of reduction ingrowth and general malaise. Treatment Tips Quarantine aquarium. Remove any dead fish immediately. Do not remove or add any live fish to the infected aquarium. Parasitic infections are highly contagious and can spread to other aquariums by nets, algae scrapers and wet hands. To speed up the life cycle of parasites and shorten treatment period, raise water temperature to 82 F (28 C). To aid osmoreregulation and ease stress of infected fish, add 1 tablespoon of API AQUARIUM SALT for each 5 gallons (19 L) of aquarium water, or 1 -1/4 cup for each 100 gallons (378 L). This medication may be used in combination with API antibacterial medications, including API MELAFIX, to help prevent scondary bacterial infection.
12.1 Mechanism of Action Praziquantel is an anthelmintic drug [see Microbiology (12.4) ] .
5 WARNINGS AND PRECAUTIONS Clinical Deterioration : Potentially life threatening clinical deterioration can occur in patients treated during the acute phase of schistosomiasis. ( 5.1 ) Central Nervous System (CNS) Effects : Praziquantel can exacerbate central nervous system pathology due to schistosomiasis. Consider whether to administer to individuals reporting a history of epilepsy and/or other signs of potential central nervous systems involvement such as subcutaneous nodules suggestive of cysticercosis. ( 5.2 ) Potential Lack of Efficacy for Acute Schistosomiasis : This has been reported in observational studies ( 5.3 ). Cardiac Arrhythmias: Bradycardia, ectopic rhythms, ventricular fibrillation, and AV blocks has been observed with praziquantel administration. Monitor patients with cardiac arrhythmias during treatment ( 5.4 ). 5.1 Clinical Deterioration The use of praziquantel in patients with schistosomiasis may be associated with clinical deterioration (for example, paradoxical reactions, serum sickness Jarisch-Herxheimer like reactions: sudden inflammatory immune response suspected to be caused by the release of schistosomal antigens). These reactions predominantly occur in patients treated during the acute phase of schistosomiasis. They may lead to potentially life-threatening events, for example, respiratory failure, encephalopathy, papilledema, and/or cerebral vasculitis. 5.2 Central Nervous System (CNS) Effects Praziquantel can exacerbate central nervous system pathology due to schistosomiasis, paragonimiasis, or Taenia solium cysticercosis. As a general rule, consider whether to administer praziquantel to individuals reporting a history of epilepsy and/or other signs of potential central nervous systems involvement such as subcutaneous nodules suggestive of cysticercosis unless the potential benefit justifies the potential risk. Hospitalize the patient for duration of treatment when schistosomiasis or fluke infection is found to be associated with cerebral cysticercosis. 5.3 Potential Lack of Efficacy During the Acute Phase of Schistosomiasis Data from two observational cohort studies in patients indicate that treatment with praziquantel in the acute phase of infection may not prevent progression from asymptomatic infection to acute schistosomiasis, or from asymptomatic infection/acute schistosomiasis into chronic phase. 5.4 Cardiac Arrhythmias Bradycardia, ectopic rhythms, ventricular fibrillation, and AV blocks has been observed with praziquantel administration. Monitor patients with cardiac arrhythmias during treatment. 5.5 Hepatic Impairment in Hepatosplenic Schistosomiasis Patients Reduced hepatic metabolism of praziquantel results in higher and sustained plasma concentrations of unmetabolized praziquantel in patients with liver impairment [see Clinical Pharmacology (12.3) ]. Monitor patients for adverse reactions when administering the recommended dose of praziquantel to hepatosplenic schistosomiasis patients with moderate or severe liver impairment (Child-Pugh Class B or C). 5.6 Concomitant Administration with Strong Cytochrome P450 Enzyme Inducers Strong Cytochrome P450 3A Enzyme (CYP 3A) Inducers Concomitant administration of strong CYP 3A inducers, such as rifampin, with praziquantel is contraindicated since therapeutically effective levels of praziquantel are unlikely to be achieved. [see Contraindications (4), Drug Interactions (7.1) and Clinical Pharmacology (12.3) ]. Moderate CYP 3A Inducers Avoid concomitant administration of praziquantel with moderate CYP 3A inducers, such as efavirenz, due to risk of a clinically significant decrease in praziquantel plasma concentrations which may lead to reduced therapeutic effect of praziquantel. [ see Drug Interactions (7.1)] . In patients receiving a clinically significant CYP 3A inducer drug who need immediate treatment for schistosomiasis, alternative agents for schistosomiasis should be considered, where possible. If praziquantel is necessary immediately, increase monitoring for reduced anthelmintic efficacy associated with praziquantel [ see Drug Interactions (7.1)] . In patients receiving a clinically significant CYP 3A inducer drug whose treatment could be delayed, discontinue the CYP 3A inducer drug at least 2 weeks to 4 weeks before administration of praziquantel and, where possible, consider starting alternative medications that are not CYP 3A inducers. The CYP 3A inducer drug can be restarted one day after completion of praziquantel treatment, if needed [see Drug Interactions (7.1) ]
4 CONTRAINDICATIONS Praziquantel is contraindicated in: Patients who previously have shown hypersensitivity to praziquantel or any of the excipients in praziquantel tablets. Patients with ocular cysticercosis; since parasite destruction within the eye that occurs because of hypersensitivity reaction to the dead parasite after treatment may cause irreversible lesions, ocular cysticercosis must not be treated with praziquantel. Patients taking strong Cytochrome P450 3A enzyme (CYP 3A) inducers, such as rifampin [see Warnings and Precautions ( 5.6) and Drug Interactions ( 7.1 , 7.2 )] . Known hypersensitivity to praziquantel or any of its ingredients. ( 4.1 ) Concomitant administration with strong Cytochrome P450 3A enzyme (CYP 3A) inducers such as rifampin. ( 4 , 5.6 , 7.1 )
6 ADVERSE REACTIONS The following serious or otherwise important adverse reactions are discussed elsewhere in the labeling: Clinical Deterioration [see Warnings and Precautions (5.1) ] Central Nervous System (CNS) Effects [see Warnings and Precautions (5.2) ] Potential Lack of Efficacy During the Acute Phase of Schistosomiasis [see Warnings and Precautions (5.3) ] Cardiac Arrhythmias [see Warnings and Precautions (5.4) ] Hepatic Impairment in Hepatosplenic Schistosomiasis Patients [see Warnings and Precautions (5.5) ] Concomitant Administration with Strong Cytochrome P450 Inducers [see Warnings and Precautions (5.6) ] The following adverse reactions associated with the use of praziquantel were identified in clinical studies, published literature or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions were observed in both adults and pediatric patients: General disorders and administration site conditions: malaise, pyrexia Nervous system disorders: headache, dizziness Gastrointestinal disorders: abdominal discomfort, nausea Skin and subcutaneous tissue disorders: urticaria Such adverse reactions may be more frequent and/or serious in patients with a heavy worm burden. Additional adverse reactions reported from worldwide post marketing experience and from publications with praziquantel and various formulations of praziquantel include: Blood and lymphatic system disorders: eosinophilia Cardiac disorders: arrhythmia (including bradycardia, ectopic rhythms, ventricular fibrillation, AV blocks) Ear and labyrinth disorders: vertigo, tinnitus Eye disorders: visual disturbance Gastrointestinal disorders: abdominal pain, bloody diarrhea, vomiting General disorders and administration site conditions: polyserositis, asthenia, fatigue, gait disturbance Hepatobiliary disorders: hepatitis Immune system disorders: allergic reaction, generalized hypersensitivity, anaphylactic reaction Metabolism and nutrition disorders: anorexia Musculoskeletal and connective tissue disorders: myalgia Nervous system disorders: convulsion, somnolence, intention tremor Respiratory, thoracic and mediastinal disorders: pneumonitis, dyspnea, wheezing Skin and subcutaneous tissue disorders: pruritus, rash, Stevens-Johnson syndrome Pediatric patients 1 to 17 years of age treated with praziquantel tablets and various formulations of praziquantel experienced similar adverse reactions as those observed in adult patients. The adverse reactions reported were malaise, headache, dizziness, abdominal discomfort (with or without nausea), pyrexia and urticaria. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Endo at 1-800-828-9393 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Directions for Use: For best results, remove activated carbon or filter cartridge from filter and continue aeration. For each 20 gallons (75 L) of water add 1 scoop (1 tsp.). For larger systems, for each 240 gallons (908 L) of water add 12 scoops (4 Tbsp.). or for each 960 gallons (3,634 L) of water add one cup. Repeat dose after 48 hours. Wait another 48 hours then change 25% of the aquarium water and add API BIO CHEM ZORB, fresh activated carbon or replace filter cartridge. Will not discolor water. Safe for use with live plants
7 DRUG INTERACTIONS Moderate CYP 3A Inducers : Avoid concomitant administration of moderate CYP 3A inducers, for example, efavirenz ( 5.6 , 7.1 ) 7.1 CYP 3A Inducers Strong and Moderate CYP 3A Inducers Concomitant administration of praziquantel with Strong and Moderate CYP 3A inducers decrease praziquantel AUC and C max [see Clinical Pharmacology (12.3) ] which may reduce the efficacy of praziquantel. Concomitant administration of a Strong CYP 3A inducer, such as rifampin, with praziquantel is contraindicated [see Contraindications (4) ]. Concomitant administration of a Moderate CYP 3A inducer, such as efavirenz, should be avoided unless the benefit outweighs the risks [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3) .] 7.2 CYP450 Inhibitors Concomitant administration of drugs that decrease the activity of drug metabolizing liver enzymes (CYP450 inhibitors), for example, cimetidine, ketoconazole, itraconazole, erythromycin, and ritonavir may increase plasma concentrations of praziquantel. In addition, grapefruit juice was also reported to produce a 1.6-fold increase in the C max and a 1.9-fold increase in the AUC of praziquantel. The effect of this exposure increase on the safety of praziquantel has not been systematically evaluated [see Dosage and Administration (2.2) ].
According to its FDA label, Praziquantel is approved for: Diagnostic Chart Gill and Skin Flukes: Very common fish parasites. Can be found on the gills, scales or skin. Not visible without the aid of magnification. Symptoms may include: darkening of skin, clamped fins, excess mucous. Fish may also swim erratically or become emaciated. Ho… For medical advice, please talk to your prescriber or pharmacist.
Praziquantel belongs to the Anthelmintic class of medications.
The FDA label lists Praziquantel as: KEEP OUT OF THE REACH OF CHILDREN. For aquarium use only. Not for human consumption or for the treatment of fish intended for human consumption. Avoid contact with skin and eyes. May cause irritation. ! WARNING: This product can expose you to chemicals including Metronidazole, which is known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.; oral route. Available strengths and packaging vary by manufacturer.
Our ingest of the FDA label for Praziquantel does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.
The FDA Enforcement Report does not show an active/ongoing recall for Praziquantel in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA record lists the approval date for Praziquantel as 2017-11-27.
The FDA label lists Endo USA, Inc. as a labeler/manufacturer of Praziquantel. Multiple firms may market generics of the same molecule.
Loading full data from Know Your Drugs Institute…